Follow
Gilles Salles
Gilles Salles
Université Claude Bernard Lyon 1
Verified email at chu-lyon.fr
Title
Cited by
Cited by
Year
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
SH Swerdlow, E Campo, SA Pileri, NL Harris, H Stein, R Siebert, ...
Blood, The Journal of the American Society of Hematology 127 (20), 2375-2390, 2016
81782016
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
B Coiffier, E Lepage, J Brière, R Herbrecht, H Tilly, R Bouabdallah, ...
New England Journal of Medicine 346 (4), 235-242, 2002
66862002
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
B Coiffier, E Lepage, J Brière, R Herbrecht, H Tilly, R Bouabdallah, ...
New England Journal of Medicine 346 (4), 235-242, 2002
66832002
Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma
SJ Schuster, MR Bishop, CS Tam, EK Waller, P Borchmann, JP McGuirk, ...
New England Journal of Medicine 380 (1), 45-56, 2019
31822019
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron, L Dacheux, G Salles, P Solal-Celigny, P Bardos, P Colombat, ...
Blood, The Journal of the American Society of Hematology 99 (3), 754-758, 2002
24262002
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron, L Dacheux, G Salles, P Solal-Celigny, P Bardos, P Colombat, ...
Blood, The Journal of the American Society of Hematology 99 (3), 754-758, 2002
24192002
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte
P Feugier, A Van Hoof, C Sebban, P Solal-Celigny, R Bouabdallah, ...
J Clin Oncol 23 (18), 4117-4126, 2005
18932005
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
G Salles, JF Seymour, F Offner, A López-Guillermo, D Belada, L Xerri, ...
The Lancet 377 (9759), 42-51, 2011
12322011
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
G Salles, JF Seymour, F Offner, A López-Guillermo, D Belada, L Xerri, ...
The Lancet 377 (9759), 42-51, 2011
12292011
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma
AK Gopal, BS Kahl, S De Vos, ND Wagner-Johnston, SJ Schuster, ...
New England Journal of Medicine 370 (11), 1008-1018, 2014
12072014
The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma
KJ Savage, S Monti, JL Kutok, G Cattoretti, D Neuberg, L De Leval, ...
Blood 102 (12), 3871-3879, 2003
10282003
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response
S Monti, KJ Savage, JL Kutok, F Feuerhake, P Kurtin, M Mihm, B Wu, ...
Blood 105 (5), 1851-1861, 2005
9732005
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response
S Monti, KJ Savage, JL Kutok, F Feuerhake, P Kurtin, M Mihm, B Wu, ...
Blood 105 (5), 1851-1861, 2005
9732005
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆
M Dreyling, M Ghielmini, S Rule, G Salles, M Ladetto, SH Tonino, ...
Annals of Oncology 32 (3), 298-308, 2021
915*2021
Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation
P Colombat, G Salles, N Brousse, P Eftekhari, P Soubeyran, V Delwail, ...
Blood, The Journal of the American Society of Hematology 97 (1), 101-106, 2001
7252001
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
S Horwitz, OA O'Connor, B Pro, T Illidge, M Fanale, R Advani, NL Bartlett, ...
The Lancet 393 (10168), 229-240, 2019
6792019
Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed
C Thieblemont, F Berger, C Dumontet, I Moullet, F Bouafia, P Felman, ...
Blood, The Journal of the American Society of Hematology 95 (3), 802-806, 2000
6602000
The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee
E Campo, ES Jaffe, JR Cook, L Quintanilla-Martinez, SH Swerdlow, ...
Blood, The Journal of the American Society of Hematology 140 (11), 1229-1253, 2022
6432022
Prognostic significance of survivin expression in diffuse large B-cell lymphomas
C Adida, C Haioun, P Gaulard, E Lepage, P Morel, J Briere, H Dombret, ...
Blood, The Journal of the American Society of Hematology 96 (5), 1921-1925, 2000
6252000
Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA)
O Hermine, C Haioun, E Lepage, MF d'Agay, J Briere, C Lavignac, G Fillet, ...
6161996
The system can't perform the operation now. Try again later.
Articles 1–20